Repligen Corp.

NASDAQ:RGEN   4:00:00 PM EDT
185.30
+5.13 (+2.85%)
4:22:05 PM EDT: $185.30 0.00 (0.00%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)10.29B
Current PE61.85
Forward PE 58.09
2yr Forward PE 62.81
See more stats
Estimates Current Quarter
Revenue$186.58 Million
Adjusted EPS$0.58
See more estimates
10-Day MA$184.86
50-Day MA$174.32
200-Day MA$183.73
See more pivots

Repligen Corp. Stock, NASDAQ:RGEN

41 Seyon Street, Building 1, Waltham, Massachusetts 02453
United States of America
Phone: +1.781.250.0111
Number of Employees: 1852

Description

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration, Process Analytics, and Proteins. The Chromatography product includes a range of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The Process Analytics products complement and support filtration, chromatography and proteins in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins product franchise is represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.